ClearFactAll topics

Do the 2025 US tariffs help the US economy?

US tariffs in 2025 · 5 peer-reviewed studies for, 9 against

Key takeaways

Stronger evidence: Against

Verdict

Tariffs can work as a policy lever: classic evidence shows countries with market power may set higher tariffs where foreign supply is inelastic, and recent U.S. episodes demonstrate tariffs can re-route supply chains and induce some production relocation. But the best empirical work on the modern U.S. experience finds that broad tariffs are largely paid at home through higher duty-inclusive import prices, with meaningful real-income losses. Micro evidence at the border and in stores indicates high pass-through and limited foreign price concession, implying incidence on U.S. firms/consumers. General-equilibrium analyses of the 2018 trade war similarly conclude that consumer and input-user losses plus retaliation outweigh gains, with large trade declines and welfare costs. Modeling of the 2025 “Liberation Day” tariff concept reinforces the same hinge: without retaliation and with careful recycling of tariff revenue, gains might be modest; with plausible retaliation and supply-chain linkages, losses can be large. Bottom line: unless tariffs are narrowly targeted, paired with credible non-retaliation or negotiated concessions, and designed to minimize input cost spillovers, the evidence weight points to net economic harm.

Strongest study on each side

Ranked by citation count.

Strongest study for

Strongest study against

Open the interactive page →

The evidence

For (5)

Supply Chain Diversification and Resilience (IMF Working Papers, 2025)

Ahn and Tan develop a general equilibrium trade model showing that supply chain diversification can enhance resilience against adverse trade shocks like tariffs, though at a cost to efficiency. The analysis suggests that targeted diversification of imports most exposed to shocks and positioned upstream can improve welfare when trade shock probability is sufficiently high.

Against (9)

The Impact of U.S. Tariffs on the Pharmaceutical Industry and Medicine Access in Europe: Challenges, Opportunities, and Future Outlook (Hospital Pharmacy, 2025)

Eleonora Castellana and Maria Rachele Chiappetta

This peer-reviewed article examines how 2025 US tariffs on pharmaceutical imports increase drug costs (several hundred dollars per family annually) and threaten patient access to essential generic and biosimilar medicines. The study highlights supply chain disruptions, therapy delays, and negative health outcomes from tariffs described as economic warfare affecting public health in both the US and Europe.

Frequently asked questions

Who actually pays for US tariffs?

Research on the 2018 tariffs found near-complete pass-through into US import prices, meaning US firms and consumers bore most of the cost. One analysis of the 2025 tariffs found lower pass-through to consumer prices, with part of the effect absorbed elsewhere in the supply chain.

Do tariffs bring back manufacturing jobs?

Evidence is mixed. One model finds tariffs can raise manufacturing employment in the long run, while another finds broad tariffs cause output losses concentrated in manufacturing because factories rely on imported parts.

Do the 2025 tariffs raise consumer prices?

Studies using matched trade and spending data show tariffs translate into higher household costs across various consumption categories. Research on pharmaceutical tariffs also points to higher drug costs and possible risks to access to generic and biosimilar medicines.

How does retaliation affect the impact of tariffs?

Retaliation is a key factor. Modeling of the 2025 tariffs finds possible modest US gains with no retaliation, but sizable welfare losses when other countries respond with their own tariffs.

Related questions